Smith, R. M. et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 2018; 378:1408-1418. Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa1715546?query=featured_home. Last accessed October 2018.
 European Medicines Agency. Apalutamide CHMP meeting highlights. Available at: https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-november-2018. Last accessed November 2018.
 Hong JH, Kim IY. Non-metastatic Castration-Resistant Prostate Cancer. Korean J Urol. 2014 Mar;55(3):153-60. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3956942/. Last accessed October 2018.
 Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol. 2010; 17(Suppl 2): S72–S79. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2935714/. Last accessed October 2018.
 Saad F, et al. The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J. 2015;9(3-4):90-96.
 American Cancer Society. Survival Rates for Prostate Cancer. Available at: www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging/survival-rates.html. Last accessed October 2018.
 Clegg NJ, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72:1494-1503.
 FDA. FDA approves new treatment for a certain type of prostate cancer using novel clinical trial endpoint. Available at https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm596768.htm. Last accessed October 2018.
 Pan-Canadian Oncology Drug Review. Available at: https://cadth.ca/sites/default/files/pcodr/pcodr_apalutamide_erleada_crpc_in_cgr%20.pdf. Last accessed October 2018.
 ERLYAND®. Australian Product Information. Available at: https://www.janssen.com/australia/sites/www_janssen_com_australia/files/prod_files/live/erlyand_pi.pdf Last accessed October 2018.
 ERLEADA® Identificação Do Medicamento. Available at: https://www.janssen.com/brasil/sites/www_janssen_com_brazil/files/prod_files/live/erleada_pub_vp.pdf . Last accessed October 2018.
Collaborating in more than 150 countries.
By clicking on a link below, you may enter a different part of this website, or a website outside of Janssen.com.
These sections or websites are governed by their own Legal and Privacy Policies.
Europe, Middle East & Africa (EMEA)
Janssen receives positive CHMP opinion for ERLEADA™ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease
Nov 16, 2018